Frontlight ResearchEarly access
Active, not recruitingEarly phase 1
A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors
Key facts
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Where
- Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, and Uniondale, United StatesSee the 7 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Early phase 1
- People taking part
- 11 people enrolled
- Started
- 5 Jan 2024
- Expected to end
- 5 Jan 2027
- Type of study
- Interventional
- Treatments tested
- 68Ga-PSMA-11 PET Scans
- Record updated
- 3 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- Ability to understand and the willingness to sign (or their legally acceptable representative (LAR) must sign) a written informed consent document
- Adults ≥ 18 years old
- Suspicion for or histologically or cytologically confirmed and previously treated HGG or brain metastases from a primary extracranial malignancy
- Lesion size ≥ 1 cm (for the lesion to be biopsied)
- ECOG performance status ≤ 2 (Karnofsky ≥ 60%)
- Planned to undergo biopsy/resection of brain lesion
Who cannot take part
- Inability to undergo a PET scan (e.g., claustrophobia or noncompatible implant in case PET/MR is performed)
- Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiacarrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Patients with severe allergy to both iodinated and gadolinium contrast
- Pregnant or nursing female. All women of childbearing potential must have a documented negative serum or urine pregnancy test <1 week before study
Where in United States
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities)Basking Ridge, United States
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)Commack, United States
- Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, United States
- Memorial Sloan Kettering Monmouth (All Protocol Activities)Middletown, United States
- Memorial Sloan Kettering Bergen (All Protocol Activities)Montvale, United States
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, United States
- Memorial Sloan Kettering Nassau (All Protocol Activities)Uniondale, United States
About the trial
What the trial wants to find out
The purpose of this study is to find out whether 68Ga-PSMA-11 PET/CT is effective in assessing tumor uptake (tumor activity seen in cancerous tissue) in participants with high-grade glioma/HGG or brain metastases.
The group in the trial
- Participants with high-grade gliomaTreatment being tested
Participants with newly diagnosed or recurrent high-grade glioma/HGG or brain metastases
Treatment: 68Ga-PSMA-11 PET Scans
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Investigator-Initiated Study to Evaluate PSMA Expression in Patients With High-Grade Gliomas or Brain Metastases With 68Ga-PSMA-11 PET
- Record updated
- 3 December 2025